Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Briacell Therapeutics Corp (NQ: BCTX )

1.010 +0.010 (+1.00%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jul 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 52,819
Open 1.010
Bid (Size) 1.020 (48)
Ask (Size) 1.050 (104)
Prev. Close 1.000
Today's Range 1.010 - 1.090
52wk Range 0.9500 - 7.590
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BCTX Stock Earnings: BriaCell Therapeutics Beats EPS for Q3 2024
BCTX stock results show that BriaCell Therapeutics beat analyst estimates for earnings per share the third quarter of 2024. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are a hot topic as investors return to trading on Tuesday following the long holiday weekend! 
Via InvestorPlace

Performance

YTD
-81.09%
-81.09%
1 Month
-27.86%
-27.86%
3 Month
-63.80%
-63.80%
6 Month
-81.05%
-81.05%
1 Year
-84.17%
-84.17%

More News

Read More
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
BCTX Stock Earnings: BriaCell Therapeutics Reported Results for Q2 2024
Via InvestorPlace
BriaCell: An Emerging Immuno - Oncology Company
Via Talk Markets
Exposures Product Safety
New Treatments May Help Those With Advanced Breast Cancer Live Longer
Via StatePoint Media
Another BriaCell Therapeutics Goal: A Better Treatment For Prostate Cancer
Via Talk Markets
Get Rich Quick With These 3 Penny Stocks to Buy Now
Via InvestorPlace
Topics Economy
Exposures Economy
BriaCell Therapeutics' Cancer Drug Shows Preliminary Survival, Clinical Benefit In Pretreated Patients
Via Benzinga
Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023
Via FinancialNewsMedia
Exposures Product Safety
BriaCell Therapeutics Corp. CEO is Featured in an Interview With SmallCapsDaily
Via NewMediaWire
BriaCell Therapeutics Corp. CEO is Featured in an Interview With SmallCapsDaily
Via TheNewswire.com
BriaCell Therapeutics Corp. CEO is Featured in an Interview With SmallCapsDaily
Via NewMediaWire
Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer
Via FinancialNewsMedia
BriaCell Therapeutics' Mission: Destroy Breast & Prostate Cancers
Via Talk Markets
BriaCell Announces Positive End of Phase II Meeting with the FDA for Bria-IMT(TM) Combination in Advanced Metastatic Breast Cancer
Via Talk Markets
BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
Via News Direct
Topics Death
Exposures Death
BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
Via TheNewswire.com
Topics Death
Exposures Death
BriaCell's Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
Via Benzinga
BriaCell’s Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients
Via TheNewswire.com
Topics Stocks
Exposures Product Safety US Equities
BriaCell’s Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients
Via News Direct
Exposures Product Safety
BriaCell's Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients
Via Benzinga
IPA’s Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies
From ImmunoPrecise Antibodies
Via Business Wire
Why KnowBe4 Shares Jumped Over 28%; Here Are 79 Biggest Movers From Yesterday
Via Benzinga
Why Is BriaCell (BCTX) Stock Moving Today?
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.